Today: 2 June 2026
Browse Category

Pharmaceuticals 24 April 2026 - 9 May 2026

Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom

Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom

Hims & Hers Health shares rose 10.2% to $28.27 on Friday ahead of first-quarter results due Monday. Analysts expect Q1 revenue near $616.9 million and earnings of 3 cents per share. The company recently reached a deal with Novo Nordisk to offer Ozempic and Wegovy, and added Eli Lilly’s Zepbound and Foundayo to its platform. The FDA is considering tighter rules on compounding GLP-1 drugs.
9 May 2026
···
Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax shares jumped 13% Friday after first-quarter revenue reached $139.5 million, beating estimates. Licensing and partner payments, including $30 million from Pfizer’s Matrix-M deal, offset weak COVID-19 vaccine demand. The stock traded at $10.45 with volume over 8.4 million shares. Investors await the company’s appearance at BofA’s health-care conference on May 13.
8 May 2026
···
Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma said it will advance clinical candidates for hantavirus after a cruise-ship outbreak killed three people, with no lead drug named yet. WHO confirmed five hantavirus cases on the MV Hondius, three fatal, and said person-to-person spread is limited. Traws shares jumped 21.8% after the announcement. The company has no approved products and recently raised $10 million in private funding.
8 May 2026
···
Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax reported first-quarter revenue of $139.5 million, beating analyst expectations but down sharply from $666.7 million a year earlier. Licensing and partner payments, including $30 million from Pfizer, offset weak COVID-19 vaccine demand. Shares rose 1.7% Thursday after a 15.6% jump Wednesday, with trading volume spiking to 16.5 million shares. Product sales fell to $42.2 million, while licensing and other revenue reached $97.3 million.
7 May 2026
··
Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, including $300 million upfront, to gain access to a mid-stage eye-disease drug, PER-001. Eylea, Bayer’s top-selling eye drug, saw 2025 sales fall 5.9% to €3.11 billion amid generic competition. The deal awaits antitrust and shareholder approval. PER-001 is in Phase II trials for glaucoma and diabetic retinopathy.
6 May 2026
··
Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax reported first-quarter revenue of $139.5 million, beating estimates as licensing and partner payments, including $30 million from Pfizer, offset weak COVID-19 vaccine sales. Shares rose 15.6% to $9.36 in afternoon trading. Product sales dropped to $42.2 million from $621.7 million a year ago. The company maintained its 2026 adjusted revenue forecast of $230 million to $270 million.
6 May 2026
··
Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk raised its 2026 outlook after early U.S. sales of its new Wegovy weight-loss pill surpassed 2 million prescriptions since January, beating expectations. Shares jumped as much as 9.2% in Copenhagen. Adjusted first-quarter sales fell 10% to 70.06 billion crowns, but reported net sales rose 24% to 96.82 billion crowns after a U.S. drug pricing provision reversal.
6 May 2026
···
Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer posted first-quarter adjusted earnings of 75 cents per share on $14.45 billion in revenue, beating Wall Street forecasts. Sales of Eliquis and Padcev rose, offsetting steep declines in COVID products. The company maintained its 2026 revenue and profit outlook. Research and development expenses increased 12% as Pfizer invested in oncology and obesity drugs.
5 May 2026
···
Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Pharmaceuticals said its drug volixibat met the main goal in a 158-patient Phase 2b trial for primary sclerosing cholangitis, reducing itch scores more than placebo. Shares rose about 9% after the announcement. The company plans a pre-NDA meeting with the FDA this summer and aims to file for U.S. approval in the second half of 2026. No FDA-approved therapies currently exist for this rare liver disease.
4 May 2026
··
Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals said founder and board chair Chris Gibson will not seek re-election at the June 17 annual meeting, months after stepping down as CEO. The company reports first-quarter results May 6, with investors watching for updates on cash, clinical progress, and its AI drug platform. Recursion last reported $753.9 million in cash and narrowed its quarterly net loss. Gibson will remain chair until his term ends.
1 May 2026
··
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna’s first-quarter revenue jumped to $389 million, driven by international Covid vaccine sales, while U.S. revenue fell to $78 million. The company posted a net loss of $1.34 billion after a $900 million patent settlement charge. Shares fell 2.7% in early trading. Moderna kept its 2026 growth target and expects FDA action on its flu vaccine by August 5, 2026.
1 May 2026
·
Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly raised its 2026 revenue forecast by $2 billion after first-quarter sales jumped 56% to $19.8 billion, driven by Mounjaro and Zepbound, which brought in $12.8 billion. Adjusted earnings reached $8.55 per share. The company cited strong demand but noted lower realized prices and competition from Novo Nordisk remain risks. Foundayo, Lilly’s new oral GLP-1 pill, launched in April but was not included in the quarter’s results.
30 April 2026
··
Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva reported first-quarter adjusted earnings of 53 cents per share on $3.98 billion revenue, beating estimates as sales of Austedo, Ajovy, and Uzedy climbed. Shares jumped 11% in New York trading. The company agreed to buy Emalex Biosciences for $700 million upfront, adding a late-stage Tourette syndrome drug candidate. Global generics revenue fell 16% amid increased competition.
29 April 2026
··
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
29 April 2026
···
Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s new oral weight-loss drug Foundayo was prescribed 3,707 times in its second week on the U.S. market, well below Novo Nordisk’s oral Wegovy, which saw 18,410 prescriptions in the same period after launch. Lilly shares fell about 4% following the data, while Novo Nordisk’s U.S. shares rose nearly 6%. Foundayo was approved by the FDA on April 1 and began shipping April 6.
24 April 2026
···
Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk’s Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly’s Foundayo at 3,707, according to IQVIA data cited by analysts. Novo’s shares rose $2.24 to $40.76, while Lilly’s fell $35.26 to $882.39. Novo said its oral semaglutide lowered HbA1c by 0.83 points more than placebo in a trial of adolescents with type 2 diabetes. The company plans to seek regulatory approval for pediatric use in 2026.
24 April 2026
··
1 2 3 4 … 41

Latest articles

Swarmer Soars 38% After Cramer Shouts Out Drone Software

Swarmer Soars 38% After Cramer Shouts Out Drone Software

2 June 2026
Swarmer soared 37.7% to $78.52 after Jim Cramer called it “a natural” on “Mad Money,” sparking retail and drone investor interest despite shrinking revenue, widening losses, and execution risks around defense contracts; shares now trade over 15 times their March IPO price.
Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

2 June 2026
Abivax shares plunged 44% to €63.10 after strong Phase 3 results for obefazimod in ulcerative colitis were overshadowed by cancer and dysplasia cases in the high-dose arm, which investigators deemed unrelated to treatment, raising investor concerns over safety and regulatory risk despite meeting all efficacy endpoints.
Netflix Stock Sinks, Wall Street Turns to June 4

Netflix Stock Sinks, Wall Street Turns to June 4

2 June 2026
Netflix shares slid nearly 3% to $83.36 as investors questioned growth targets ahead of Thursday’s annual meeting, with the stock under pressure despite management maintaining 2026 revenue and margin forecasts and warning of heavier content costs in the first half.
Marathon Digital Drops as Bitcoin Tops $70,000; Eyes on AI Push

Marathon Digital Drops as Bitcoin Tops $70,000; Eyes on AI Push

2 June 2026
MARA fell 4.2% to $14.23 as bitcoin slid below $70,000, highlighting the miner’s ongoing dependence on crypto prices despite efforts to pivot toward AI and power infrastructure; analysts remain split on the new strategy, and the Long Ridge deal still faces regulatory and execution risks.
Dow, S&P inch up as AI surge faces $80 billion hurdle

Dow, S&P inch up as AI surge faces $80 billion hurdle

2 June 2026
Alphabet shares fell after announcing plans to raise $80 billion through equity offerings to fund soaring AI infrastructure costs, even as demand for its AI services exceeded supply and capital spending forecasts climbed to $180–$190 billion for 2026.
Go toTop